Abstract
Memory impairment is a result of multiple factors including amyloid-beta (Aβ) accumulation. Several receptors are mediated for Aβ transport and signaling. Moreover, blood lipids are involved in Aβ signaling pathway through these receptors. Mediated blood lipid level by statins aims to regulate Aβ signaling cascade. First, the structure of receptors was taken from the RCSB PDB database and prepared with MGLTools and AutoDock tool 4. Second, the ligand was prepared for docking through AutoDock Vina. The binding affinity was calculated, and the binding sites were determined through LigPlot+ software. Besides, pharmacokinetic properties were calculated through multiple software. Finally, a molecular dynamics (MD) simulation was conducted to evaluate ligands stability along with clustering analysis to evaluate proteins connection. Our molecular docking and dynamic analyses revealed silymarin as a potential inhibitor of acetylcholinesterase (AChE), P-glycoprotein, and angiotensin-converting enzyme 2 (ACE2) with 0.704, 0.85, and 0.83 Å for RMSD along with -114.27, -107.44, and -122.51 kcal/mol for free binding energy, respectively. Moreover, rosuvastatin and quercetin have more stability compared to silymarin and donepezil in complex with P-glycoprotein and ACE2, respectively. Eventually, based on clustering and pharmacokinetics analysis, silymarin, rosuvastatin, and quercetin are suggested to be involved in peripheral clearance of Aβ. The bioactivity effects of mentioned statins and antioxidants are predicted to be helpful in treating memory impairment in Alzheimer’s disease (AD). Nevertheless, mentioned drug effect could be improved by nanoparticles to facilitate penetration of the blood–brain barrier (BBB).
Similar content being viewed by others
Avoid common mistakes on your manuscript.
Introduction
Amyloid-β (Aβ) is the trigger of the devastative and progressive procedure of Alzheimer’s disease (AD) pathological cascade as a prominent neurodegeneration disease (Chiu et al. 2015). Aβ transport and metabolism are two aspects of the clearance pathway involved in diminishing the toxicity impact. In the transporting aspect, low-density lipoprotein receptor-related protein 1 (LRP1) and receptor for advanced glycation end-products (RAGE) have two contradicting functions in the blood–brain barrier (BBB), in which LRP1 participates in the efflux of Aβ from interstitial fluid (Cai et al. 2018). LRP1, in addition to transporting, has multiple functions for which its deletion causes early embryonic lethality (Shinohara et al. 2017). In contrast, RAGE inhibition has not depicted any fatality in the case of inhibition, thus becoming a candidate target for develo** novel AD medications (Cui et al. 2017). Above all, P-glycoprotein (P-gp) is highlighted as a modulator of AB-level in the BBB (Mohamed et al. 2016). In addition to the Aβ transporting aspect, it is worth mentioning β-site amyloid precursor protein cleaving enzyme 1 (BACE1), which involves in the amyloidogenic pathological pathway (Huang et al. 2021).
Since statins have less BBB penetration rate, they cannot influence neurons and their products in CNS. Moreover, they have a less binding affinity toward different forms of Aβ, except for silymarin which can bind to Aβ1-40 (not toxic) and Aβ fibril (toxic). In contrast, studies suggested administration of statins could attenuate Aβ accumulation (Bai et al. 2019; Mohamed et al. 2016). To explain this paradox, we could highlight Aβ receptors which most of the statins can bind to them efficiently. Statins strongly bind to RAGE, P-glycoprotein, ABCA1, and ACE2. These receptors interact with Aβ and are known to involve in its transport and clearance. In vitro studies conceptualize the extracellular V domain of (RAGE) as a key domain for ligand binding (Singh and Agrawal 2022; Tolstova et al. 2022; Yue et al. 2022). Our results also confirm this prediction and as depicted in Fig. 1, all compounds bind to this domain as the best confirmation (Fig. 1). However, the MD simulation contradicts these results. To explain this conflict, it is worthwhile to note that the RAGE receptor is attached to the membrane of cells. Hence, its interaction with other membrane compounds results in protein structure alternation. Therefore, since the complex system of membrane proteins is hard to simulate, in this study, just a simplified condition was simulated. ACE expressed by the endothelium and its action is mainly thought to be a mediator for salt balance. Nonetheless, its inhibition through small molecules was stated to prevent Aβ aggregation (** et al. 2021; Le et al. 2021). Our result finds out the high binding affinity of statins to ACE2, and it may facilitate Aβ binding for peripheral clearance.
Another important finding of this study is quercetin’s tumorigenic and mutagenic properties. Multiple studies declared the anti-tumor properties of quercetin and highlighted its role in eliminating tumors (Rauf et al. 2018; Reyes-Farias and Carrasco-Pozo 2019; Shafabakhsh and Asemi 2019; Tang et al. 2020). Its exact mechanism has not been clearly discovered; nevertheless, it is suggested to act through various mechanisms like regulating PI3K/Akt/mTOR, Wnt/-catenin, and MAPK/ERK1/2 pathways (Reyes-Farias and Carrasco-Pozo 2019) or promoting cytotoxic effects. However, Shafabakhsh et al. declare that it did not affect healthy cells (Shafabakhsh and Asemi 2019), and its mutagenic properties must be assessed through various methods. Quercetin may affect cells by inducing DNA mutation, and because cancer cells have high DNA transcription, it can affect them with a higher effect than healthy cells.
Duan et al. conducted research on APP/PS1 transgenic mice with administration of 200 mg/kg silybin once a day for 28 days, and its effect was measured in vitro and in vivo. The results revealed a decline in AChE activity (Duan et al. 2015). This research outcome acknowledges our results that show silymarin and most of the statins have high binding affinity and can inhibit AChE.
As far as β-secretase known as BACE1 has a proven high impact on cleavage and metabolism of amyloid-beta precursor protein in multiple studies (Hampel et al. 2021), new biosynthesis medicine should be focused on inhibition of this enzyme. None of the compounds analyzed in our study has a high potential effect for inhibiting this enzyme. To put all the results together, our studies suggested the potential inhibitory effects of selected ligands on hallmark proteins involved in AD pathological symptoms; nevertheless, their efficiency could be improved by designing effective nanoparticles to transport and penetrate BBB, which help to increase the bioavailability of mentioned ligands in the CNS. Moreover, one of the limitations of our study is the implementation of in vitro and in vivo assessment; therefore, further in vivo and in vitro studies are needed to fully confirm the influence of the mentioned ligands on selected receptors and prove the role of statins on amyloidogenesis pathway with involvement of RAGE, ACE2, and P-gp.
Conclusion
Memory impairment as a neurological and neurophysiological phenomenon influences patients’ life quality. Aβ accumulation as one of the factors which influence memory can be diminished through multiple treatment strategies. RAGE as a receptor transporting Aβ into the CNS and P-gp as a crucial mediator in Aβ signaling can be efficiently inhibited by statins as well as silymarin. AChE can be inhibited by quercetin more effectively than donepezil. In addition, statins can affect other proteins, including amyloid precursors like protein 2, ACE2, and TNF-α. The pharmacokinetic properties of statins and antioxidants reveal their ability to peripheral clearance of Aβ since they have a poor BBB penetration rate. Also, some of them (further study needed) including atorvastatin and quercetin may have a low ability to ameliorate the reproductive system failure and tumorigenicity.
Data Availability
The data that support the findings of this study is openly available on the request.
References
Abdulwahab DK, Ibrahim WW, Abd El-Aal RA, Abdel-Latif HA, Abdelkader NF (2021) Grape seed extract improved the fertility-enhancing effect of atorvastatin in high-fat diet-induced testicular injury in rats: involvement of antioxidant and anti-apoptotic effects. J Pharm Pharmacol 73(3):366–376
Akdeniz E, Onger ME, Bolat MS, Firat F, Gur M, Cinar O, Bakirtas M, Acıkgoz A, Erdemir F (2020) Effect of atorvastatin on spermatogenesis in rats: a stereological study. Trop J Pharm Res 19(12):2609–2614
Bai D, ** G, Zhang D, Zhao L, Wang M, Zhu Q, Zhu L, Sun Y, Liu X, Chen X (2019) Natural silibinin modulates amyloid precursor protein processing and amyloid-β protein clearance in APP/PS1 mice. J Physiol Sci 69(4):643–652
Banfi C, Baetta R, Gianazza E, Tremoli E (2017) Technological advances and proteomic applications in drug discovery and target deconvolution: identification of the pleiotropic effects of statins. Drug Discov Today 22(6):848–869
Bhat A, Dalvi H, Jain H, Rangaraj N, Singh SB, Srivastava S (2021) Perspective insights of repurposing the pleiotropic efficacy of statins in neurodegenerative disorders: an expository appraisal. Current Research in Pharmacology and Drug Discovery 2:100012
Borah A, Paul R, Choudhury S, Choudhury A, Bhuyan B, Das Talukdar A, Dutta Choudhury M, Mohanakumar KP (2013) Neuroprotective potential of silymarin against CNS disorders: insight into the pathways and molecular mechanisms of action. CNS Neurosci Ther 19(11):847–853
Cai Z, Qiao PF, Wan CQ, Cai M, Zhou NK, Li Q (2018) Role of blood-brain barrier in Alzheimer’s disease. J Alzheimers Dis 63(4):1223–1234. https://doi.org/10.3233/jad-180098
Chiu C, Miller MC, Monahan R, Osgood DP, Stopa EG, Silverberg GD (2015) P-glycoprotein expression and amyloid accumulation in human aging and Alzheimer’s disease: preliminary observations. Neurobiol Aging 36(9):2475–2482
Cui H, Su S, Cao Y, Ma C, Qiu W (2021) The altered anatomical distribution of ACE2 in the brain with Alzheimer’s disease pathology. Front Cell Dev Biol 9:1581
Cui L, Cai Y, Cheng W, Liu G, Zhao J, Cao H, Tao H, Wang Y, Yin M, Liu T (2017) A novel, multi-target natural drug candidate, matrine, improves cognitive deficits in Alzheimer’s disease transgenic mice by inhibiting Aβ aggregation and blocking the RAGE/Aβ axis. Mol Neurobiol 54(3):1939–1952
Dahlin JL, Nissink JWM, Strasser JM, Francis S, Higgins L, Zhou H, Zhang Z, Walters MA (2015) PAINS in the assay: chemical mechanisms of assay interference and promiscuous enzymatic inhibition observed during a sulfhydryl-scavenging HTS. J Med Chem 58(5):2091–2113
Davis R, Reveles KR, Ali SK, Mortensen EM, Frei CR, Mansi I (2015) Statins and male sexual health: a retrospective cohort analysis. J Sex Med 12(1):158–167
Dege N, Gökce H, Doğan OE, Alpaslan G, Ağar T, Muthu S, Sert Y (2022) Quantum computational, spectroscopic investigations on N-(2-((2-chloro-4, 5-dicyanophenyl) amino) ethyl)-4-methylbenzenesulfonamide by DFT/TD-DFT with different solvents, molecular docking and drug-likeness researches. Colloids Surf A 638:128311
Duan S, Guan X, Lin R, Liu X, Yan Y, Lin R, Zhang T, Chen X, Huang J, Sun X (2015) Silibinin inhibits acetylcholinesterase activity and amyloid β peptide aggregation: a dual-target drug for the treatment of Alzheimer’s disease. Neurobiol Aging 36(5):1792–1807
Gökce H, Şen F, Sert Y, Abdel-Wahab BF, Kariuki BM, El-Hiti GA (2022) Quantum computational investigation of (E)-1-(4-methoxyphenyl)-5-methyl-N'-(3-phenoxybenzylidene)-1H-1,2,3-triazole-4-carbohydrazide. Molecules 27(7). https://doi.org/10.3390/molecules27072193
Hampel H, Vassar R, De Strooper B, Hardy J, Willem M, Singh N, Zhou J, Yan R, Vanmechelen E, De Vos A (2021) The β-secretase BACE1 in Alzheimer’s disease. Biol Psychiat 89(8):745–756
Huang Y-Y, Fang N, Luo H-R, Gao F, Zou Y, Zhou L-L, Zeng Q-P, Fang S-s, **ao F, Zheng Q (2020) RP1, a RAGE antagonist peptide, can improve memory impairment and reduce Aβ plaque load in the APP/PS1 mouse model of Alzheimer’s disease. Neuropharmacology 180:108304
Humphrey W, Dalke A, Schulten K (1996) VMD: visual molecular dynamics. J Mol Graph 14(1):33–38
Husain I, Akhtar M, Abdin MZ, Islamuddin M, Shaharyar M, Najmi A (2018) Rosuvastatin ameliorates cognitive impairment in rats fed with high-salt and cholesterol diet via inhibiting acetylcholinesterase activity and amyloid beta peptide aggregation. Hum Exp Toxicol 37(4):399–411
Husain I, Akhtar M, Vohora D, Abdin MZ, Islamuddin M, Najmi AK (2017) Rosuvastatin attenuates high-salt and cholesterol diet induced neuroinflammation and cognitive impairment via preventing nuclear factor KappaB pathway. Neurochem Res 42(8):2404–2416
Husain I, Khan S, Khan S, Madaan T, Kumar S, Najmi AK (2019) Unfolding the pleiotropic facades of rosuvastatin in therapeutic intervention of myriads of neurodegenerative disorders. Clin Exp Pharmacol Physiol 46(4):283–291
Jagadeb M, Rath SN, Sonawane A (2019) In silico discovery of potential drug molecules to improve the treatment of isoniazid-resistant Mycobacterium tuberculosis. J Biomol Struct Dyn 37(13):3388–3398. https://doi.org/10.1080/07391102.2018.1515116
** L, Liu C, Zhang N, Zhang R, Yan M, Bhunia A, Zhang Q, Liu M, Han J, Siebert H-C (2021) Attenuation of human lysozyme amyloid fibrillation by ACE inhibitor captopril: a combined spectroscopy, microscopy, cytotoxicity, and docking study. Biomacromol 22(5):1910–1920
** P, Pan Y, Pan Z, Xu J, Lin M, Sun Z, Chen M, Xu M (2018) Alzheimer-like brain metabolic and structural features in cholesterol-fed rabbit detected by magnetic resonance imaging. Lipids Health Dis 17(1):61. https://doi.org/10.1186/s12944-018-0705-9
Jo S, Kim T, Iyer VG, Im W (2008) CHARMM-GUI: a web-based graphical user interface for CHARMM. J Comput Chem 29(11):1859–1865
Kim S, Lee J, Jo S, Brooks III CL, Lee HS, Im W (2017) CHARMM-GUI ligand reader and modeler for CHARMM force field generation of small molecules. In: Wiley Online Library
Knapp B, Lederer N, Omasits U, Schreiner W (2010) vmdICE: a plug-in for rapid evaluation of molecular dynamics simulations using VMD. J Comput Chem 31(16):2868–2873
Laskowski RA, Swindells MB (2011) LigPlot+: multiple ligand–protein interaction diagrams for drug discovery. In: ACS Publications
Le D, Brown L, Malik K, Murakami S (2021) Two opposing functions of angiotensin-converting enzyme (ACE) that links hypertension, dementia, and aging. Int J Mol Sci 22(24):13178
Lee J-S, Kim ES, Lee HG (2017) Improving the water solubility and antimicrobial activity of silymarin by nanoencapsulation. Colloids Surf B 154:171–177
Liu H, Hou T (2016) CaFE: a tool for binding affinity prediction using end-point free energy methods. Bioinformatics 32(14):2216–2218
Lütjohann D, Meichsner S, Pettersson H (2012) Lipids in Alzheimer’s disease and their potential for therapy. Clin Lipidol 7(1):65–78
Malathi K, Anbarasu A, Ramaiah S (2019) Identification of potential inhibitors for Klebsiella pneumoniae carbapenemase-3: a molecular docking and dynamics study. J Biomol Struct Dyn 37(17):4601–4613. https://doi.org/10.1080/07391102.2018.1556737
Mawuenyega KG, Sigurdson W, Ovod V, Munsell L, Kasten T, Morris JC, Yarasheski KE, Bateman RJ (2010) Decreased clearance of CNS β-amyloid in Alzheimer’s disease. Science 330(6012):1774–1774
Mirzaei N, Davis N, Chau TW, Sastre M (2022) Astrocyte reactivity in Alzheimer’s disease: therapeutic opportunities to promote repair. Curr Alzheimer Res 19(1):1–15
Mohamed LA, Keller JN, Kaddoumi A (2016) Role of P-glycoprotein in mediating rivastigmine effect on amyloid-β brain load and related pathology in Alzheimer's disease mouse model. Biochim Biophys Acta Mol Basis Dis 1862(4):778–787
Mori T, Paris D, Town T, Rojiani AM, Sparks DL, Delledonne A, Crawford F, Abdullah LI, Humphrey JA, Dickson DW (2001) Cholesterol accumulates in senile plaques of Alzheimer disease patients and in transgenic APPsw mice. J Neuropathol Exp Neurol 60(8):778–785
Morris GM, Huey R, Lindstrom W, Sanner MF, Belew RK, Goodsell DS, Olson AJ (2009) AutoDock4 and AutoDockTools4: automated docking with selective receptor flexibility. J Comput Chem 30(16):2785–2791
O’Boyle NM, Banck M, James CA, Morley C, Vandermeersch T, Hutchison GR (2011) Open Babel: an open chemical toolbox. J Cheminformatics 3(1):1–14
Omolaoye TS, Halabi MO, Mubarak M, Cyril AC, Duvuru R, Radhakrishnan R, Du Plessis SS (2022) Statins and male fertility: is there a cause for concern? Toxics 10(10):627
Pasieka A, Panek D, Szałaj N, Espargaró A, Więckowska A, Malawska B, Sabaté R, Bajda M (2021) Dual inhibitors of amyloid-β and tau aggregation with amyloid-β disaggregating properties: extended in cellulo, in silico, and kinetic studies of multifunctional anti-Alzheimer’s agents. ACS Chem Neurosci 12(11):2057–2068
Phillips JC, Hardy DJ, Maia JD, Stone JE, Ribeiro JV, Bernardi RC, Buch R, Fiorin G, Hénin J, Jiang W (2020) Scalable molecular dynamics on CPU and GPU architectures with NAMD. J Chem Phys 153(4):044130
Pires DE, Blundell TL, Ascher DB (2015) pkCSM: predicting small-molecule pharmacokinetic and toxicity properties using graph-based signatures. J Med Chem 58(9):4066–4072
Porwal O, Ameen MSM, Anwer ET, Uthirapathy S, Ahamad J, Tahsin A (2019) Silybum marianum (milk thistle): review on Its chemistry, morphology, ethno medical uses, phytochemistry and pharmacological activities. J Drug Deliv Ther 9(5):199–206
Rauf A, Imran M, Khan IA, ur-Rehman M, Gilani SA, Mehmood Z, Mubarak MS (2018) Anticancer potential of quercetin: a comprehensive review. Phytother Res 32(11):2109–2130
Reyes-Farias M, Carrasco-Pozo C (2019) The anti-cancer effect of quercetin: molecular implications in cancer metabolism. Int J Mol Sci 20(13):3177
Sadeghi M, Sabbaghziarani F, Soleimani P, Ashtarimajelan MR, Zafari F (2021) Association of atorvastatin with increased growth and quality of immature mouse oocytes in-vitro. Sci J Kurdistan Univ Medical Sci 26(4):30–37
Sander T (2001) OSIRIS property explorer. Organic Chemistry Portal
Sanner MF (1999) Python: a programming language for software integration and development. J Mol Graph Model 17(1):57–61
Schramm S, Gunesch S, Lang F, Saedtler M, Meinel L, Högger P, Decker M (2018) Investigations into neuroprotectivity, stability, and water solubility of 7-O-cinnamoylsilibinin, its hemisuccinate and dehydro derivatives. Arch Pharm 351(11):1800206
Shafabakhsh R, Asemi Z (2019) Quercetin: a natural compound for ovarian cancer treatment. J Ovarian Res 12(1):1–9
Shannon P, Markiel A, Ozier O, Baliga NS, Wang JT, Ramage D, Amin N, Schwikowski B, Ideker T (2003) Cytoscape: a software environment for integrated models of biomolecular interaction networks. Genome Res 13(11):2498–2504. https://doi.org/10.1101/gr.1239303
Shinohara M, Tachibana M, Kanekiyo T, Bu G (2017) Role of LRP1 in the pathogenesis of Alzheimer’s disease: evidence from clinical and preclinical studies: thematic review series: ApoE and lipid homeostasis in Alzheimer’s disease. J Lipid Res 58(7):1267–1281
Shiri F, Pirhadi S, Ghasemi JB (2019) Dynamic structure based pharmacophore modeling of the acetylcholinesterase reveals several potential inhibitors. J Biomol Struct Dyn 37(7):1800–1812. https://doi.org/10.1080/07391102.2018.1468281
Singh A, Kumar A, Verma RK, Shukla R (2020) Silymarin encapsulated nanoliquid crystals for improved activity against beta amyloid induced cytotoxicity. Int J Biol Macromol 149:1198–1206
Singh H, Agrawal DK (2022) Therapeutic potential of targeting the receptor for advanced glycation end products (RAGE) by small molecule inhibitors. Drug Dev Res 83(6):1257–1269
Soleimani V, Delghandi PS, Moallem SA, Karimi G (2019) Safety and toxicity of silymarin, the major constituent of milk thistle extract: an updated review. Phytother Res 33(6):1627–1638. https://doi.org/10.1002/ptr.6361
Szklarczyk D, Franceschini A, Wyder S, Forslund K, Heller D, Huerta-Cepas J, Simonovic M, Roth A, Santos A, Tsafou KP, Kuhn M, Bork P, Jensen LJ, von Mering C (2015) STRING v10: protein-protein interaction networks, integrated over the tree of life. Nucleic Acids Res 43:D447-452. https://doi.org/10.1093/nar/gku1003
Tang S-M, Deng X-T, Zhou J, Li Q-P, Ge X-X, Miao L (2020) Pharmacological basis and new insights of quercetin action in respect to its anti-cancer effects. Biomed Pharmacother 121:109604
Tijms BM, Vermunt L, Zwan MD, van Harten AC, van der Flier WM, Teunissen CE, Scheltens P, Visser PJ, ADNI, (2018) Pre-amyloid stage of Alzheimer’s disease in cognitively normal individuals. Ann Clin Transl Neurol 5(9):1037–1047
Tolstova AP, Adzhubei AA, Mitkevich VA, Petrushanko IY, Makarov AA (2022) Docking and molecular dynamics-based identification of interaction between various beta-amyloid isoforms and RAGE receptor. Int J Mol Sci 23(19):11816
Toth PP, Dayspring TD (2011) Drug safety evaluation of rosuvastatin. Expert Opin Drug Saf 10(6):969–986
Trott O, Olson AJ (2010) AutoDock Vina: improving the speed and accuracy of docking with a new scoring function, efficient optimization, and multithreading. J Comput Chem 31(2):455–461
Tvrdý V, Pourová J, Jirkovský E, Křen V, Valentová K, Mladěnka P (2021) Systematic review of pharmacokinetics and potential pharmacokinetic interactions of flavonolignans from silymarin. Med Res Rev 41(4):2195–2246. https://doi.org/10.1002/med.21791
Urina-Jassir M, Pacheco-Paez T, Paez-Canro C, Urina-Triana M (2021) Statin associated adverse reactions in Latin America: a sco** review. BMJ Open 11(10):e050675
Vuorio A, Kovanen PT, Raal F (2022) Cholesterol-lowering drugs for high-risk hypercholesterolemia patients with COVID-19 while on Paxlovid™ therapy. Future Virol. https://doi.org/10.2217/fvl-2022-0060
Wolozin B (2011) Statins and therapy of Alzheimer’s disease: questions of efficacy versus trial design. Alzheimers Res Ther 3(6):1–3
Yang W, Shi H, Zhang J, Shen Z, Zhou G, Hu M (2017) Effects of the duration of hyperlipidemia on cerebral lipids, vessels and neurons in rats. Lipids Health Dis 16(1):26. https://doi.org/10.1186/s12944-016-0401-6
Yue Q, Song Y, Liu Z, Zhang L, Yang L, Li J (2022) Receptor for advanced glycation end products (RAGE): a pivotal hub in immune diseases. Molecules 27(15):4922
Acknowledgements
The authors are grateful to the research vice-chancellor of the Iran University of Medical Sciences (IUMS), Tehran, Iran. All methods and analyses were performed according to Ethics Committee instructions (IUMS Alzheimer’s clinical research section) with the ethical code: IR.IUMS.FMD.REC.1400.409.
Funding
This project is supported by the deputy of research at the Iran University of Medical Sciences (grant number: 20441).
Author information
Authors and Affiliations
Contributions
Auob Rustamzadeh contributed to the study’s conception and design, along with writing the first draft of the manuscript and data analysis. Material preparation, figures, data collection, and analysis were performed by Armin Ariaei. Mehran Ebrahimi Shah-abadi and Fatemeh Moradi contributed to writing the first draft of the manuscript. Rastegar Rahmani Tanha, Nader Sadigh, and Mohsen Marzban contribute to writing and editing. Mahdi Heydari and Vahid Tavakolian Ferdousie contribute to reviewing. All authors commented on previous versions of the manuscript. All authors read and approved the final manuscript.
Corresponding author
Ethics declarations
Competing Interests
The authors declare no competing interests.
Additional information
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.
About this article
Cite this article
Shah-abadi, M.E., Ariaei, A., Moradi, F. et al. In Silico Interactions of Natural and Synthetic Compounds with Key Proteins Involved in Alzheimer’s Disease: Prospects for Designing New Therapeutics Compound. Neurotox Res 41, 408–430 (2023). https://doi.org/10.1007/s12640-023-00648-1
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s12640-023-00648-1